Karanja 1987.

Study characteristics
Methods	Subjects were assigned randomly to one of two treatment regimens: 1) 8 wk of calcium (phase I) followed by a washout period of 4 wk on placebo and then 8 wk of placebo (phase II); or 2) 8 wk of placebo (phase I) followed by a 4‐wk washout period on placebo and then 8 wk of calcium (phase II)
Participants	32 normotensive subjects recruited from the community and from the Outpatient Clinic of the Oregon Health Sciences University Aged 21‐70 yrs
Interventions	Intervention group: One gram elemental calcium was supplied in two tablets of calcium carbonate (BioCal) or effervescent calcium (mono‐calcium citrate). Control group: placebo tablets Trial duration: 8 weeks
Outcomes	Total Cholesterol Triglycerides HDL‐Cholesterol LDL‐Cholesterol
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Subjects were assigned randomly to one of two treatment regimens.
Allocation concealment (selection bias)	Unclear risk	Medication was dispensed every 2 wk with placebo or calcium taken at bedtime. One gram elemental calcium was supplied in two tablets of calcium carbonate (BioCal) or effervescent calcium (mono‐calcium citrate).
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Subjects were assigned randomly to one of two treatment regimens.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Blood samples were collected at the end of the baseline evaluation and again at the end of phases I and II.
Incomplete outcome data (attrition bias) All outcomes	Low risk	32 participants were randomised and 27 reported in the results.
Selective reporting (reporting bias)	High risk	Blood pressure was not reported.
Other bias	Unclear risk	No other bias reported